EL7.AI
StocksMedium•5 November 2026•
1 min read

Korsana Biosciences Reports $456.2 Million Cash Position and Funding Runway into 2029

Key Facts

1Korsana Biosciences reported cash and cash equivalents of approximately $456.2 million as of September 30, 2026, expected to fund operations into 2029.
2The company completed its merger with Cyclerion Therapeutics along with a concurrent $380 million private placement.
3The company expects Phase 1 healthy volunteer data for KRSA-028 in mid-2027.

Korsana Biosciences reported cash and cash equivalents of approximately $456.2 million as of September 30, 2026. The company stated in a GlobeNewswire release that this capital position is expected to fund its operations into 2029. This follows the completion of its merger with Cyclerion Therapeutics, which included a concurrent $380 million private placement.

KRSA closed at $30.56 on November 4, 2026, prior to the disclosure of financial results showing a net loss of $46.4 million for the third quarter of 2026. Looking ahead, the company expects to release Phase 1 healthy volunteer data for its KRSA-028 program in mid-2027, with interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027 or the first quarter of 2028.

Open on chart